Advancing Immunotherapy in Metastatic Breast Cancer.

Opinion Statement: Despite many advances in the treatment of breast cancer, the development of metastatic disease remains an incurable and frequent cause of cancer death for women worldwide. An improved understanding of the role of host immunosurveillance in modulating breast cancer disease biology,...

Descripción completa

Detalles Bibliográficos
Publicado en:Current Treatment Options in Oncology Vol. 18; no. 6; pp. 1 - 16
Autores principales: Mansour, Mariam, Teo, Zhi, Luen, Stephen, Loi, Sherene, Teo, Zhi Ling, Luen, Stephen J
Formato: review tables/charts Journal Article
Publicado: Springer Nature Jun2017
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=123991955&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 123991955
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        15272729
        3KHC
      jtl: Current Treatment Options in Oncology
      issn: 15272729
      maglogo: N
    pubinfo:
      dt: Jun2017
      vid: 18
      iid: 6
      pid: 237
      pub: Springer Nature
      place: New York, New York
    artinfo:
      ui:
        123991955
        123991955
        NLM28534250
        123991955
        10.1007/s11864-017-0478-9
        NLM28534250
        123991955
      ppf: 1
      ppct: 15
      formats:
        fmt:
          @attributes:
            type: P
      tig:
        atl: Advancing Immunotherapy in Metastatic Breast Cancer.
      aug:
        au:
          Mansour, Mariam
          Teo, Zhi
          Luen, Stephen
          Loi, Sherene
          Teo, Zhi Ling
          Luen, Stephen J
        affil: Division of Research, Peter MacCallum Cancer Centre , University of Melbourne , 305 Grattan St Melbourne 3000 Australia
      sug:
        subj:
          Breast Neoplasms Immunology
          Breast Neoplasms Therapy
          Immunotherapy Methods
          Immunotherapy Adverse Effects
          Drug Therapy
          Neoplasm Staging
          Lymphocytes Drug Effects
          Immunity, Cellular
          Immune System Physiology
          Antineoplastic Agents Pharmacodynamics
          Neoplasm Metastasis
          Antibodies, Monoclonal Pharmacodynamics
          Cell Physiology Immunology
          Antineoplastic Agents Therapeutic Use
          Signal Transduction Drug Effects
          Disease Management
          Lymphocyte Subsets Immunology
          Lymphocytes Immunology
          Patient Selection
          Lymphocyte Subsets Drug Effects
          Prognosis
          Lymphocytes Metabolism
          Cell Physiology
          Antibodies, Monoclonal Therapeutic Use
          Cell Physiology Drug Effects
          Lymphocyte Subsets Metabolism
          Breast Neoplasms Metabolism
          Breast Neoplasms Diagnosis
          Female
          Female
      ab: Opinion Statement: Despite many advances in the treatment of breast cancer, the development of metastatic disease remains an incurable and frequent cause of cancer death for women worldwide. An improved understanding of the role of host immunosurveillance in modulating breast cancer disease biology, as well as impressive survival benefits seen to checkpoint blockade in other malignancies have provided great hope for an expanding role of immunotherapies in breast cancer management. While these novel therapies are currently being investigated in clinical trials, signals of efficacy, and tolerability in early phase studies suggest these will eventually make their way into standard practice algorithms. Ongoing research has highlighted a high degree of intertumoural heterogeneity in tumour lymphocytic infiltrates, suggesting some tumours or subtypes are more immunogenic than others. Furthermore, tumour intrinsic mechanisms of immune evasion are beginning to be uncovered, potentially representing key therapeutic targets to use in combination with checkpoint blockade, exemplifying the emerging concept of personalised medicine approaches to immune therapies. Subsequently, different immunotherapeutic strategies may be required based on stratification by these factors-for the minority of tumours with a high level of pre-existing immunity, immune checkpoint blockade monotherapy may be sufficient. However, for the majority of tumours with lower levels of pre-existing immunity, combination approaches will likely be required to achieve maximal therapeutic effect. Results of ongoing clinical trials including combinations with chemotherapy, radiation therapy, and targeted therapies are eagerly awaited.
      pubtype: Academic Journal
      doctype:
        review
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N